Posts With Tag Oncology

AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.

Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.

Discover AstraZeneca's June 2025 Block Listing Interim Review, detailing securities management and share option plans. Key insights on compliance and financial performance.

AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.

AstraZeneca's Form 6-K reveals CEO Pascal Soriot's acquisition of 8,970 shares post-vesting. Key insights on performance, compliance, and tax obligations included.

AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.

Explore Gilead Sciences' Q1 2025 financial report, highlighting $6.647B revenue, $1.315B net income, and a positive outlook for investors. Key insights on profitability and R&D investments.

AstraZeneca's latest SEC Form 6-K reveals promising results from the DESTINY-Breast11 trial, highlighting Enhertu's potential to redefine treatment for high-risk HER2-positive breast cancer patients.

AstraZeneca's Calquence receives EU approval for untreated MCL, offering new hope with improved survival rates. This report details clinical trial results and market implications.

AstraZeneca PLC's recent Form 6-K reveals Non-Executive Director Karen Knudsen's purchase of 1,400 ADSs, reflecting confidence in the company's future. Key insights on compliance and market sentiment.

Explore AstraZeneca PLC's May 2025 Form 6-K report detailing 1.55B voting rights and regulatory compliance.

Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.